ZYMEWORKS INC(NASDAQ:ZYME) stock News

ZYME Latest News, Press Relases and Analysis

All

Press Releases

6 days ago - By: Zymeworks Inc.

Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025

6 days ago - By: Zymeworks Inc.

Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025

3 months ago - By: Benzinga - Mentions: GSAT PGY ADV REAL ...

Earnings Scheduled For August 7, 2025

7 days ago - By: Benzinga - Mentions: APP COHR ALB PPG ...

Broadcom To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Tuesday

8 days ago - By: Zymeworks Inc.

Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference

8 days ago - By: Zymeworks Inc.

Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference

13 days ago - By: Zymeworks Inc.

Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer

13 days ago - By: Zymeworks Inc.

Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer

2 months ago - By: Stocktwits - Mentions: VFMO IWMW

Zymeworks Stock Tanks Over 17% After Cancer Drug Candidate Update

2 months ago - By: Zymeworks Inc.

Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager

2 months ago - By: Zymeworks Inc.

Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager

2 months ago - By: Zymeworks Inc.

Zymeworks Announces Participation in Upcoming Investor Conferences

2 months ago - By: Zymeworks Inc.

Zymeworks Announces Participation in Upcoming Investor Conferences

2 months ago - By: Zacks Investment Research - Mentions: CRMD KOD ALVO

Kodiak Q2 Loss Wider Than Expected, Pipeline Development in Focus

2 months ago - By: Zacks Investment Research - Mentions: CRMD IMVT ALVO

Immunovant's Q1 Loss Narrower Than Expected, Pipeline in Focus

2 months ago - By: Zacks Investment Research

Zymeworks (ZYME) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

2 months ago - By: Zymeworks Inc.

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

2 months ago - By: Zymeworks Inc.

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

3 months ago - By: Zacks Investment Research - Mentions: BRTX

Zymeworks Inc. (ZYME) Tops Q2 Earnings and Revenue Estimates

3 months ago - By: Zymeworks Inc.

Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results

3 months ago - By: Zymeworks Inc.

Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results

3 months ago - By: Zymeworks Inc.

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate

3 months ago - By: Zymeworks Inc.

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate

3 months ago - By: Zymeworks Inc.

Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

3 months ago - By: Zymeworks Inc.

Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

4 months ago - By: Zacks Investment Research

All You Need to Know About Zymeworks (ZYME) Rating Upgrade to Buy

5 months ago - By: Stocktwits - Mentions: IWM VTI

Zymeworks’ Drug Gets Conditional Approval For Biliary Tract Cancer Treatment In China: Retail Sentiment Refuses To Budge

5 months ago - By: Zymeworks Inc.

Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer

5 months ago - By: Zymeworks Inc.

Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer

5 months ago - By: Zymeworks Inc.

ZYMEWORKS INC (ZYME) Stock News

ZYME Latest News, Press Relases and Analysis

Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025

Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025

Earnings Scheduled For August 7, 2025

Broadcom To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Tuesday

Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference

Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference

Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer

Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer

Zymeworks Stock Tanks Over 17% After Cancer Drug Candidate Update

Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager

Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager

Zymeworks Announces Participation in Upcoming Investor Conferences

Zymeworks Announces Participation in Upcoming Investor Conferences

Kodiak Q2 Loss Wider Than Expected, Pipeline Development in Focus

Immunovant's Q1 Loss Narrower Than Expected, Pipeline in Focus

Zymeworks (ZYME) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

Zymeworks Inc. (ZYME) Tops Q2 Earnings and Revenue Estimates

Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate

Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

All You Need to Know About Zymeworks (ZYME) Rating Upgrade to Buy

Zymeworks’ Drug Gets Conditional Approval For Biliary Tract Cancer Treatment In China: Retail Sentiment Refuses To Budge

Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer

Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer

Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences